Sign in or Register   Sign in or Register
  |  

Mouse Anti-PRKAG2 Recombinant Antibody (F-2) (CBMAB-A2589-YC)

Provided herein is a Mouse monoclonal antibody against Human Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2. The antibody can be used for immunoassay techniques, such as WB, IP, IF, ELISA.
See all PRKAG2 antibodies

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat
Clone
F-2
Antibody Isotype
IgG
Application
WB, IP, IF, ELISA

Basic Information

Specificity
Human, Mouse, Rat
Antibody Isotype
IgG
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
protein kinase, AMP-activated, gamma 2 non-catalytic subunit
Introduction
The protein encoded by this gene is a regulatory subunit of the AMP-activated protein kinase (AMPK). AMPK is a heterotrimer consisting of an alpha catalytic subunit, andnon-catalytic beta and gamma subunits. AMPK is an important energy-sensing enzyme that
Entrez Gene ID
Human51422
Mouse108099
Rat373545
UniProt ID
HumanQ9UGJ0
MouseQ91WG5
RatQ6V7V4
Alternative Names
AA571379; BB036179; Prkaac
Function
AMP/ATP-binding subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Gamma non-catalytic subunit mediates binding to AMP, ADP and ATP, leading to activate or inhibit AMPK: AMP-binding results in allosteric activation of alpha catalytic subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and preventing dephosphorylation of catalytic subunits. ADP also stimulates phosphorylation, without stimulating already phosphorylated catalytic subunit. ATP promotes dephosphorylation of catalytic subunit, rendering the AMPK enzyme inactive.
Biological Process
ATP biosynthetic processManual Assertion Based On ExperimentTAS:BHF-UCL
Cellular response to glucose starvationManual Assertion Based On ExperimentIBA:GO_Central
Fatty acid biosynthetic processIEA:UniProtKB-KW
Glycogen metabolic processManual Assertion Based On ExperimentIMP:BHF-UCL
Intracellular signal transductionManual Assertion Based On ExperimentIMP:BHF-UCL
Negative regulation of protein kinase activityManual Assertion Based On ExperimentIDA:BHF-UCL
Positive regulation of peptidyl-threonine phosphorylationManual Assertion Based On ExperimentIMP:BHF-UCL
Positive regulation of protein kinase activityManual Assertion Based On ExperimentIMP:BHF-UCL
Protein phosphorylationManual Assertion Based On ExperimentIBA:GO_Central
Regulation of catalytic activityManual Assertion Based On ExperimentIBA:GO_Central
Regulation of fatty acid metabolic processManual Assertion Based On ExperimentIMP:BHF-UCL
Regulation of fatty acid oxidationManual Assertion Based On ExperimentTAS:BHF-UCL
Regulation of glucose importManual Assertion Based On ExperimentTAS:BHF-UCL
Regulation of glycolytic processManual Assertion Based On ExperimentIMP:BHF-UCL
Sterol biosynthetic processManual Assertion Based On ExperimentTAS:BHF-UCL
Cellular Location
cytoplasm
cytosol
extracellular space
nucleoplasm
nucleotide-activated protein kinase complex
nucleus
Involvement in disease
Wolff-Parkinson-White syndrome (WPWS):
A supernormal conduction disorder characterized by the presence of one or several accessory atrioventricular connections, which can lead to episodes of sporadic tachycardia.
Cardiomyopathy, familial hypertrophic 6 (CMH6):
A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. CMH6 patients present Wolff-Parkinson-White ventricular preexcitation, enlarged myocytes without myofiber disarray, and glycogen-containing cytosolic vacuoles within cardiomyocytes.
Glycogen storage disease of heart lethal congenital (GSDH):
Rare disease which leads to death within a few weeks to a few months after birth, through heart failure and respiratory compromise.
PTM
Phosphorylated by ULK1; leading to negatively regulate AMPK activity and suggesting the existence of a regulatory feedback loop between ULK1 and AMPK.
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-PRKAG2 Recombinant Antibody (F-2)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare